(Il Sole 24 Ore Radiocor) - Milano, 6 mag - The German pharmaceutical and chemical company Bayer said it has agreed to acquire Perfuse Therapeutics in a deal valued up to 2.45 billion dollars, comprising a 300 million upfront payment and additional development, regulatory and commercial milestone payments.

Perfuse Therapeutics is a biopharmaceutical company carrying out transformational research into the treatment of ischemia-induced ocular diseases. With the acquisition, Bayer will hold the full rights for PER 001, a small molecule endothelin receptor antagonist currently in Phase III clinical development for the treatment of glaucoma and diabetic retinopathy (DR). Bayer noted that this represents one of the first potential treatments for glaucoma and DRI being studied for its ability to improve the visual field for glaucoma patients and to improve contrast sensitivity and reduce ischemia in DR patients.

The acquisition is subject to and will become effective after receiving the necessary antitrust clearances and Perfuse.

stockholder approvals.

(RADIOCOR) 06-05-26 11:40:06 (0363) 5 NNNN